Oruka Therapeutics (ORKA) Total Non-Current Liabilities (2014 - 2025)
Oruka Therapeutics' quarterly Total Non-Current Liabilities came in at $12.8 million in Q3 2025, up 14.07% year-on-year from $11.2 million in Q3 2024, and up 19.55% quarter-over-quarter from $10.7 million in Q2 2025.
Oruka Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $12.8 million in Q3 2025.
- For the quarter ending Q3 2025, Total Non-Current Liabilities rose 14.07% year-over-year to $12.8 million; the trailing twelve-month figure through Sep 2025 stood at $12.8 million (up 14.07% YoY), and the FY2015 full-year result was $1.5 million, up 8.12% from the prior year.
- Total Non-Current Liabilities for Q3 2025 stood at $12.8 million, up from $10.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $12.8 million in Q3 2025, with the low at $784000.0 in Q3 2023.
- Average Total Non-Current Liabilities over 3 years is $8.0 million, with a median of $10.8 million recorded in 2025.
- Year-over-year, Total Non-Current Liabilities surged 1328.57% in 2024 and climbed 14.07% in 2025.
- Tracing ORKA's Total Non-Current Liabilities over 3 years: stood at $784000.0 in 2023, then surged by 1328.57% to $11.2 million in 2024, then advanced by 14.07% to $12.8 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $12.8 million (Q3 2025), $10.7 million (Q2 2025), and $11.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 12.78 Mn |
| Jun 30, 2025 | 10.69 Mn |
| Mar 31, 2025 | 10.97 Mn |
| Sep 30, 2024 | 11.20 Mn |
| Sep 30, 2023 | 784,000.00 |
| Jun 30, 2023 | 1.41 Mn |
| Dec 31, 2015 | 1.50 Mn |
| Dec 31, 2014 | 1.39 Mn |